Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Redeye: Xvivo Perfusion - Well-preserved value

Redeye re-initiates coverage of Xvivo with strengthened conviction following a deep dive into its clinical data and that of key competitor TransMedics, as well as target markets. While the coronavirus crisis presents some nearer-term challenges, the case is attractive in view of Xvivo’s commercial and clinical progress, strong positioning for a surgical pick-up and undemanding valuation even after the share’s recent rebound. Read more and download the research update: https://bit.ly/36FMHNa   Start following companies at Redeye to receive the latest equity research within Life

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Sivula, Harri Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528160032_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Laaksonen, Reija Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528161328_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mäkelä, Antti Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528161819_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Nuutinen, David Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528162229_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Paananen, Jokke Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528162412_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Kamux Oyj - Managers' Transactions

Kamux Corporation   Managers’ Transactions    29 May at 16:30   Kamux Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Vähäpassi, Tuomo Position: Member of the Board/Deputy member Issuer: Kamux Oyj LEI: 743700KCVYIYNLPZYN56 Notification type: INITIAL NOTIFICATION Reference number: 743700KCVYIYNLPZYN56_20200528162710_2 ____________________________________________ Transaction date: 2020-05-28 Venue not applicable Instrument type: SHARE ISIN: FI4000206750 Nature of the

Change in the number of shares and votes in Projektengagemang following conversion

The number of shares and votes in Projektengagemang Sweden AB (publ) has changed due to conversion of 6 300 class A shares to 6 300 class B shares.Pursuant to the articles of association of Projektengagemang, a holder of a class A share is entitled to request that the share is converted into a class B share. In May 2020, 6 300 class A shares have been converted into 6 300 class B shares, at the request of shareholders. After the conversion, as of 05/29 2020, the total number of shares and votes in Projektengagemang Sweden AB (publ) amounted to 24 555 677 and 73 085 693, respectively. 5

Neste Corporation - Managers' Transactions, Lindfors (disposal)

Neste Corporation, Managers' Transactions, 29 May 2020 at 4.15 p.m. (EET) ____________________________________________ Person subject to the notification requirementName: Lindfors, Lars PeterPosition: Other senior managerIssuer: Neste OyjLEI: 5493009GY1X8GQ66AM14 Notification type: INITIAL NOTIFICATIONReference number: 5493009GY1X8GQ66AM14_20200529143701_2____________________________________________ Transaction date: 2020-05-29Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009013296Nature of the transaction: DISPOSAL   Transaction

Director buys shares in Panoro Energy ASA

Mandatory notification of trade primary insidersOslo, 29 May 2020 - Panoro Energy ASA (the "Company" or "Panoro" with OSE Ticker: PEN) announces that Hilde Ådland, Non-Executive Director of the Company, has today purchased 10,000 shares at NOK 9.0027 each. After the transaction, Ms. Ådland owns 19,097 shares in the Company. This information is subject to the disclosure requirements pursuant to section 5 -12 and section 4-2 of the Norwegian Securities Trading Act.    Enquiries Panoro Energy ASA                                     +44 203 405 1060Qazi Qadeer, Chief Financial

Notification of trade

Hamilton, Bermuda. May 29, 2020. Flex LNG Ltd (“Flex LNG” or the “Company”) hereby announces that the following primary insider has today acquired shares in Flex LNG: Mr. Øystein M. Kalleklev, Chief Executive Officer of Flex LNG Management AS, has today acquired 5,000 shares in Flex LNG at a price of NOK 41.80. Following the transaction, Mr. Kalleklev holds 45,000 shares in Flex LNG and options for a further 60,000 shares. These options have a strike price of $ 14.10 per share equivalent to about NOK 137 per share with USD/NOK 9.7 and vest equally one third over a three-year vesting

Vestas wins 41 MW order in China

News release from Vestas ChinaBeijing, 29 May 2020Vestas has received an order for a project in China that includes the supply of 17 V120-2.2 MW wind turbines with 141m towers delivered in 2.4 MW Power Optimised Mode, as well as a 5-year Active Output Management 4000 (AOM 4000) service agreement.Deliveries are expected to begin in the fourth quarter of 2020, with commissioning planned for the same quarter.The project and customer are undisclosed.For updated Vestas photographs and videos, please visit our media images page on: https://www.vestas.com/en/media/images.For more

INTRODUCING URBANISTA LONDON: SOUND AND SILENCE

Silence the outside world or let the sound in with Urbanista’s new active noise cancelling earphonesFor immediate release: 6[th] May 2020, Stockholm, Sweden – Urbanista, the Swedish lifestyle audio brand, announces the launch of Urbanista London, an active noise cancelling true wireless earphone, designed to put the listener in control. London is the latest in the brand’s true wireless headphone line-up and lives up to their tagline: ‘Designed for Life in Motion’. Boasting an in-ear style that combines secure fit and crystal clear, isolated sound with comfort, simplicity and reliability,

NATTO : INITIAL RESPONSE TO OFFERS BY KAPPA BIOSCIENCE

Oslo, Norway (29 May 2020) — Reference is made to the stock exchange notice issued on 28 May 2020 regarding an announcement of offers by Kappa Bioscience AS ("Kappa") to acquire shares in Nattopharma ASA ("NattoPharma" or the "Company") at an offer price per share of NOK 12.75 (the "Offer Price") through; (i) a contemplated voluntary offer for all shares of the Company (the "Voluntary Offer"), and (ii) an unconditional offer to acquire up 2,127,573 shares in the Company (the "Offer"). The Board of Directors of NattoPharma (the "Board") is in the process of engaging a financial advisor to

15% energy cost savings and improved indoor climate with IoT and AI

Talkpool and Myrspoven jointly deliver Smart Building solutions for energy savings and improved air quality to prime real estate companies. Results from the first commercial installations show energy savings of 10-20% AND much improved indoor climate. Hence the smart building solution improves health and wellbeing while reducing energy costs. The wireless solution with battery-powered sensors is easy to install in all kinds of buildings. Talkpool provides sensors, connectivity, data management and services. The indoor climate is monitored in real-time with Talkpool’s OY1210 LoRaWAN CO2

Cinkciarz.pl wins with Mastercard in the EU Court in 12 trademark matters

The Court of the European Union in Luxembourg agreed with Cinkciarz.pl in 12 proceedings initiated by Mastercard International, Inc. before the European Union Intellectual Property Office (EUIPO).In 2016, Mastercard filed 12 oppositions against Cinkciarz.pl trademarks comprising elements of two overlapping circles claiming that they fall within the monopoly of Mastercard trademarks.  The EUIPO at first instance agreed with Cinkciarz.pl and dismissed the oppositions on the grounds that the trademarks are not similar, but the Board of Appeals of EUIPO overruled these decisions. According

Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015

Lund, Sweden, May 29, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data from the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer, which further validates the potential of the drug. The presentation will be held at the ASCO (American Society of Clinical Oncology) Annual Meeting, which this year is being held virtually. The results from the evaluation of doses up and including 600 mg (about 10 mg/kg) show that ATOR-1015 is well tolerated,

Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial

29 May 2020 13:00 BST Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial First HER2-directed medicine to show an improvement in overall survival for previously treated metastatic gastric cancer with a 41% reduction in the risk of death vs. chemotherapy Breakthrough Therapy Designation recently granted in the USfor Enhertu in this setting Detailed results from the positive, registrational, randomised controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi

Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial

29 May 2020 13:00 BST Imfinzi showed a sustained overall survival benefit in 1st-lineextensive-stage small cell lung cancer in the Phase III CASPIAN trial ASCO data show more than 10% of patients on Imfinzi plus chemotherapy had not progressed and remained on treatment at two years vs. 2.9% on chemotherapy alone Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca's Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall

Interim Report 30[th] December 2019 to 29 March 2020

FRIDAY, 29[th] MAY, 14:00 CETJANUARY to MARCH 2020 · Net sales amounted to £28.3 million · EBITDA before special items amounted to £5,421k up 32.2% on the same quarter last year · Operating profit amounted to £3,881k · Profit before tax amounted to £854k · Cash and cash equivalents at the end of the period were £21,965k  Q2 revenues were 4.5% ahead of the same quarter last year despite the negative impact on the closure of the business on 24[th] March, one week before the end of the quarter. Continued rigorous cost control, reduction in media spend due to the COVID 19

Bondholder meetings

Reference is made to the stock exchange notice on 14 May 2020 in which it was advised that bondholder meetings were summoned for 29 May 2020 for the SOFF 04 (ISIN NO 0010713548) and the Solship Invest 1 AS bond issues (ISIN 0010779945). The proposed decisions in the summons dated 14 May 2020 were approved in both bondholder meetings today. ContactsLars Peder Solstad CEO, at +47 91 31 85 85Anders Hall Jomaas CFO, at +47 40 04 29 18 Skudeneshavn, May 29[th], 2020Solstad Offshore ASA This information is subject of the disclosure requirements according to the Norwegian

Extended cooperation with UPM in Pietarsaari

BillerudKorsnäs and UPM have entered into an agreement that will extend the supply agreement for pulp, steam and electricity for the production at BillerudKorsnäs’ mill in Pietarsaari.The original agreement was signed in 2012 in conjunction with BillerudKorsnäs’ acquisition of the Pietarsaari mill and was initially scheduled to expire in June 2022. The now agreed new supply contract is based on market conditions and will enter into force in June 2020. As part of the renegotiation, the parties have agreed that BillerudKorsnäs will pay a compensation of EUR 15 million to UPM during the coming

Share capital and total number of voting rights ultimo May 2020

Vestas Wind Systems A/S, Aarhus, 29 May 2020Company announcement No. 21/2020   Share capital and total number of voting rights ultimo May 2020 As announced on 6 May 2020, Vestas Wind Systems A/S has completed a capital reduction of nominally DKK 1,977,848 representing 1,977,848 shares of nominally DKK 1 each in connection with cancellation of treasury shares. In accordance with section 32 of the Danish Capital Markets Act, Vestas Wind Systems A/S is required to disclose the total number of voting rights and the size of the share capital in the company no later than at the end

There are no items matching the current filter
There are no more items matching the current filter
Back to top